<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05108662</url>
  </required_header>
  <id_info>
    <org_study_id>49-708</org_study_id>
    <nct_id>NCT05108662</nct_id>
  </id_info>
  <brief_title>Inflammatory Markers: HOLEP Versus TURP</brief_title>
  <official_title>Comparison of Surgical Stress in Patients Undergoing TURP Versus HOLEP Surgery by Measuring Perioperative Systemic Inflammatory Markers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Adana City Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Adana City Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of the study is to compare the systemic inflammatory markers and surgical stress response&#xD;
      in patients undergoing HOLEP or TUR-P surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Benign prostatic hyperplasia (BPH) is the most common disease in aging men worldwide, causing&#xD;
      significant difficulties and resulting in bladder outlet obstruction. Basically, surgical&#xD;
      techniques in patients with BPH are transurethral resection of the prostate (TURP), holmium&#xD;
      laser enucleation of the prostate (HOLEP), and open prostoactemy surgery. There are many&#xD;
      studies comparing the clinical outcomes of TURP and HOLEP surgery. However, to the best of&#xD;
      our knowledge, there has not been a study comparing the effects of these two types of surgery&#xD;
      on inflammatory markers and stress hormones.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2020</start_date>
  <completion_date type="Actual">August 30, 2021</completion_date>
  <primary_completion_date type="Actual">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>inflamatory markers</measure>
    <time_frame>Change from baseline WBC (109 /L) at postoperative 0th and postoperative 24th hour</time_frame>
    <description>WBC (109 /L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Stress hormone levels</measure>
    <time_frame>Change from baseline adrenaline (ng/L) at postoperative 0th and postoperative 24th hour</time_frame>
    <description>Adrenaline (ng/L)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflamatory markers</measure>
    <time_frame>Change from baseline CRP (mg/L) at postoperative 0th and postoperative 24th hour</time_frame>
    <description>CRP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflamatory markers</measure>
    <time_frame>Change from baseline IL-6 (pg/ml) and TNF-alfa (pg/ml), at postoperative 0th and postoperative 24th hour</time_frame>
    <description>IL-6 (pg/ml) and TNF-alfa (pg/ml)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>inflamatory markers</measure>
    <time_frame>Change from baseline CD4+/CD8+ at postoperative 0th and postoperative 24th hourL-6 (pg/ml) and TNF-alfa (pg/ml)</time_frame>
    <description>CD4+/CD8+</description>
  </primary_outcome>
  <primary_outcome>
    <measure>stress hormone levels</measure>
    <time_frame>Change from baseline cortisol (microg/dl) at postoperative 0th and postoperative 24th hour</time_frame>
    <description>Cortisol (microg/dl)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Prostate Hyperplasia</condition>
  <arm_group>
    <arm_group_label>HOLEP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with a prostate volume greater than 80 g</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TURP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with a prostate volume less than 80 g</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery method</intervention_name>
    <description>Patients were subdivided into two groups according to their prostate volume</description>
    <arm_group_label>HOLEP</arm_group_label>
    <arm_group_label>TURP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA scores I-III patients&#xD;
&#xD;
          -  having benign prostatic hyperplasia&#xD;
&#xD;
          -  undergoing HOLEP or TURP surgery under general anesthesia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  immune system disease,&#xD;
&#xD;
          -  diabetes mellitus,&#xD;
&#xD;
          -  malignancy other than prostate disease,&#xD;
&#xD;
          -  history of steroid use,&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baris Arslan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Adana City Training and Research Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Adana City Training and Research Hospital</name>
      <address>
        <city>Adana</city>
        <zip>01170</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Adana City Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Baris Arslan, MD</investigator_full_name>
    <investigator_title>Baris Arslan, MD, Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

